|
FOR
IMMEDIATE RELEASE
February
24, 2004.
Guava
Technologies Inc. and Amersham Biosciences, the life sciences business
of Amersham, have signed an exclusive three-year distribution agreement
covering the territory of Japan for Guava Personal Cell Analysis
(PCA) systems, reagents and software modules.
Amersham
Biosciences broadens range of Cellular Analysis solutions with Guava
Technologies' Japanese distribution deal …
Guava
Technologies Inc. and Amersham Biosciences, the life sciences business
of Amersham, have signed an exclusive three-year distribution agreement
covering the territory of Japan for Guava Personal Cell Analysis
(PCA) systems, reagents and software modules.
By
adding the Guava PCA systems to its portfolio, Amersham Biosciences
now offers micro-cytometry instruments, reagents and analysis software.
Guava's products have broad applications in scientific research,
drug discovery, cell counting, and optimisation of commercial bioproduction.
The Guava PCA systems offer an integrated, optimised approach that
takes the guesswork out of single cell analysis and counting. Based
on patented micro-capillary technology, the Guava PCA systems are
available in three configurations.
With
flexible and ultra-compact systems, cell analysis with the Guava
PCA requires only a few microlitres of sample volume. This results
in substantial savings in precious and expensive cells, reagents
and compounds. Guava offers a range of assays and dedicated software
modules enhancing the Guava PCA system's overall ease-of-use.
The
Guava PCA systems are complementary to Amersham Biosciences' cellular
analysis reagents and IN Cell Analyzer platforms to provide a comprehensive
cellular analysis offering, supported by Amersham Biosciences' distribution,
marketing, sales and support franchise. Compatibility of reagents
from both companies across the IN Cell Analyzer and PCA platforms
will simplify and improve cellular analysis applications and extend
a more complete systems offering to our customers.
Keiko
Hattori, president, Japan and International at Amersham Biosciences
says: "We are delighted to have signed this distribution agreement
with Guava Technologies. In the past, technology based instrumentation
has created bottlenecks rather than removed them in all cell based
research and cell health monitoring applications. The agreement
means we can offer customers powerful instrumentation coupled with
integrated software and optimised reagents, helping them improve
the laboratories productivity and work flow."
"We
are very pleased and excited to be working with Amersham Biosciences"
says Paul Kinnon vice president commercial development, Guava Technologies.
"Our experience in the decentralized cellular analysis market,
coupled with the extensive marketing and commercial support of Amersham
Biosciences, will strengthen our presence in the vibrant Japanese
life sciences market and promote higher productivity in drug development
and scientific research as it relates to cell analysis."
The
Guava Technologies products now available from Amersham Biosciences
in Japan include: The Guava PCA, PCA-96 and PCA-96 AFP (Auto Fluorescent
Protein) Platforms with Software modules and reagent kits including
Guava ViaCount® , Nexin, Express, MultiCaspase , TUNEL, Cell
Cycle Software Modules and the Express AFP Software Module for the
PCA-96 AFP.
CONTACTS:
|